Skip to main content

Menu

British National Formulary June 2025 Update

This update contains 8 significant changes, 4 dose changes, 2 new monographs and 4 new preparations.

Significant Changes:

  • Bimekizumab: new indication and dose for hidradenitis suppurativa.
  • Chloroquine: updated pregnancy and breast-feeding advice when used for rheumatic disease.
  • Contraceptives, hormonal: inclusion of guidance for use of combined oral contraceptives for preventive treatment of ovarian cancer in at-risk females.
  • Hydroxychloroquine sulfate: updated pregnancy and breast-feeding advice.
  • Malaria, prophylaxis: updated guidance.
  • Sepsis: updated guidance on management.
  • Sympathomimetics: updated guidance for septic shock.
  • Tuberculosis: updated guidance for multi-drug resistant tuberculosis.

 

Dose Changes:

  • Colchicine [update to dosing for prophylaxis of familial Mediterranean fever].
  • Rilpivirine [update to dosing for HIV-1 infection].
  • Sodium hyaluronate with trehalose [update to dosing for dry eye conditions].
  • Vocabria® (cabotegravir) [update to dosing for HIV-1 infection].

 

New Monographs:

  • Briumvi® [ublituximab]
  • Duvyzat® [givinostat].

 

New Preparations: Apretude® 30 mg film-coated tablets [cabotegravir]; Apretude® 600 mg prolonged-release suspension for injection [cabotegravir]; Budenofalk® suppositories [budesonide]; Netildex® eye gel [dexamethasone with netilmicin]